AG˹ٷ

STOCK TITAN

[8-K] Chemed Corporation Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

Cel-Sci Corp. (CVM) filed a Form 4 showing CEO & Director Geert R. Kersten was granted 25,000 stock options on 07/28/2025. The options carry an $8.20 exercise price, expire 07/27/2035, and vest in three equal annual tranches starting one year from grant. No common-stock purchases or sales were reported in Table I.

After the grant, Kersten directly holds 175,157 derivative securities (options). The transaction represents routine equity compensation and introduces only immaterial dilution given Cel-Sci’s outstanding share base. The filing contains no financial results, guidance changes, or other corporate events.

Cel-Sci Corp. (CVM) ha presentato un Modulo 4 che mostra come il CEO e Direttore Geert R. Kersten abbia ricevuto 25.000 opzioni su azioni il 28/07/2025. Le opzioni hanno un prezzo di esercizio di 8,20 $, scadono il 27/07/2035 e maturano in tre tranche annuali uguali a partire da un anno dopo la concessione. Non sono stati segnalati acquisti o vendite di azioni ordinarie nella Tabella I.

Dopo la concessione, Kersten detiene direttamente 175.157 titoli derivati (opzioni). L’operazione rappresenta una normale forma di compensazione azionaria e comporta una diluizione trascurabile, considerando la base azionaria in circolazione di Cel-Sci. Il documento non contiene risultati finanziari, modifiche alle previsioni o altri eventi societari.

Cel-Sci Corp. (CVM) presentó un Formulario 4 que muestra que el CEO y Director Geert R. Kersten 𳦾ó 25,000 opciones sobre acciones el 28/07/2025. Las opciones tienen un precio de ejercicio de 8,20 $, vencen el 27/07/2035 y se consolidan en tres tramos anuales iguales a partir de un año después de la concesión. No se reportaron compras o ventas de acciones ordinarias en la Tabla I.

Después de la concesión, Kersten posee directamente 175,157 valores derivados (opciones). La transacción representa una compensación accionaria rutinaria e implica una dilución insignificante dado el número de acciones en circulación de Cel-Sci. El documento no contiene resultados financieros, cambios en las previsiones ni otros eventos corporativos.

Cel-Sci Corp. (CVM)은 CEO � 이사� Geert R. Kersten가 2025� 7� 28일에 25,000� 스톡옵션� 부여받았음� 보여주는 Form 4� 제출했습니다. 해당 옵션은 행사가 8.20달러이며, 2035� 7� 27일에 만료되고, 부여일로부� 1� 후부� 3년에 걸쳐 동일� 비율� 권리가 취득됩니�. � I에는 보통� 매매 내역� 보고되지 않았습니�.

옵션 부� � Kersten은 직접 175,157개의 파생 증권(옵션)� 보유하고 있습니다. 이번 거래� 일상적인 주식 보상으로, Cel-Sci� 발행 주식 수를 고려� � 희석 효과� 미미합니�. 제출 서류에는 재무 실적, 가이던� 변� 또는 기타 기업 이벤트가 포함되어 있지 않습니다.

Cel-Sci Corp. (CVM) a déposé un formulaire 4 indiquant que le PDG et directeur Geert R. Kersten a reçu 25 000 options d'achat d'actions le 28/07/2025. Les options ont un prix d'exercice de 8,20 $, expirent le 27/07/2035 et se répartissent en trois tranches annuelles égales à compter d'un an après l'attribution. Aucun achat ou vente d'actions ordinaires n'a été signalé dans le tableau I.

Après l'attribution, Kersten détient directement 175 157 titres dérivés (options). Cette opération constitue une rémunération en actions courante et n'entraîne qu'une dilution négligeable compte tenu du nombre d'actions en circulation de Cel-Sci. Le dépôt ne contient aucun résultat financier, changement de prévisions ou autre événement d'entreprise.

Cel-Sci Corp. (CVM) reichte ein Formular 4 ein, das zeigt, dass CEO und Direktor Geert R. Kersten am 28.07.2025 mit 25.000 Aktienoptionen ausgestattet wurde. Die Optionen haben einen Ausübungspreis von 8,20 $, laufen am 27.07.2035 ab und werden in drei gleichen jährlichen Tranchen ab einem Jahr nach der Gewährung fällig. In Tabelle I wurden keine Käufe oder Verkäufe von Stammaktien gemeldet.

Nach der Gewährung hält Kersten direkt 175.157 derivative Wertpapiere (Optionen). Die Transaktion stellt eine routinemäßige Aktienvergütung dar und führt aufgrund der ausstehenden Aktienbasis von Cel-Sci nur zu einer unerheblichen Verwässerung. Die Einreichung enthält keine Finanzergebnisse, Prognoseänderungen oder andere Unternehmensereignisse.

Positive
  • Incentive alignment: Option grant ties CEO compensation to future share performance, potentially motivating value creation.
Negative
  • Potential dilution: New options add to overhang, albeit modestly.
  • No performance conditions: Time-based vesting may weaken pay-for-performance linkage.

Insights

TL;DR: Routine CEO option grant; negligible balance-sheet impact.

The 25k option award aligns the CEO with shareholders but is too small to materially affect dilution or valuation. Strike set at $8.20—likely near or slightly above market—so value is contingent on future price appreciation. Total options held (175k) remain minor versus Cel-Sci’s float. No cash outlay or revenue effect; investor impact neutral.

TL;DR: Standard incentive structure; governance risk unchanged.

Three-year graded vesting promotes retention and long-term focus. Absence of performance hurdles limits pay-for-performance rigor, yet award size is moderate. Filing discloses direct ownership, enhancing transparency. Overall, governance profile remains stable.

Cel-Sci Corp. (CVM) ha presentato un Modulo 4 che mostra come il CEO e Direttore Geert R. Kersten abbia ricevuto 25.000 opzioni su azioni il 28/07/2025. Le opzioni hanno un prezzo di esercizio di 8,20 $, scadono il 27/07/2035 e maturano in tre tranche annuali uguali a partire da un anno dopo la concessione. Non sono stati segnalati acquisti o vendite di azioni ordinarie nella Tabella I.

Dopo la concessione, Kersten detiene direttamente 175.157 titoli derivati (opzioni). L’operazione rappresenta una normale forma di compensazione azionaria e comporta una diluizione trascurabile, considerando la base azionaria in circolazione di Cel-Sci. Il documento non contiene risultati finanziari, modifiche alle previsioni o altri eventi societari.

Cel-Sci Corp. (CVM) presentó un Formulario 4 que muestra que el CEO y Director Geert R. Kersten 𳦾ó 25,000 opciones sobre acciones el 28/07/2025. Las opciones tienen un precio de ejercicio de 8,20 $, vencen el 27/07/2035 y se consolidan en tres tramos anuales iguales a partir de un año después de la concesión. No se reportaron compras o ventas de acciones ordinarias en la Tabla I.

Después de la concesión, Kersten posee directamente 175,157 valores derivados (opciones). La transacción representa una compensación accionaria rutinaria e implica una dilución insignificante dado el número de acciones en circulación de Cel-Sci. El documento no contiene resultados financieros, cambios en las previsiones ni otros eventos corporativos.

Cel-Sci Corp. (CVM)은 CEO � 이사� Geert R. Kersten가 2025� 7� 28일에 25,000� 스톡옵션� 부여받았음� 보여주는 Form 4� 제출했습니다. 해당 옵션은 행사가 8.20달러이며, 2035� 7� 27일에 만료되고, 부여일로부� 1� 후부� 3년에 걸쳐 동일� 비율� 권리가 취득됩니�. � I에는 보통� 매매 내역� 보고되지 않았습니�.

옵션 부� � Kersten은 직접 175,157개의 파생 증권(옵션)� 보유하고 있습니다. 이번 거래� 일상적인 주식 보상으로, Cel-Sci� 발행 주식 수를 고려� � 희석 효과� 미미합니�. 제출 서류에는 재무 실적, 가이던� 변� 또는 기타 기업 이벤트가 포함되어 있지 않습니다.

Cel-Sci Corp. (CVM) a déposé un formulaire 4 indiquant que le PDG et directeur Geert R. Kersten a reçu 25 000 options d'achat d'actions le 28/07/2025. Les options ont un prix d'exercice de 8,20 $, expirent le 27/07/2035 et se répartissent en trois tranches annuelles égales à compter d'un an après l'attribution. Aucun achat ou vente d'actions ordinaires n'a été signalé dans le tableau I.

Après l'attribution, Kersten détient directement 175 157 titres dérivés (options). Cette opération constitue une rémunération en actions courante et n'entraîne qu'une dilution négligeable compte tenu du nombre d'actions en circulation de Cel-Sci. Le dépôt ne contient aucun résultat financier, changement de prévisions ou autre événement d'entreprise.

Cel-Sci Corp. (CVM) reichte ein Formular 4 ein, das zeigt, dass CEO und Direktor Geert R. Kersten am 28.07.2025 mit 25.000 Aktienoptionen ausgestattet wurde. Die Optionen haben einen Ausübungspreis von 8,20 $, laufen am 27.07.2035 ab und werden in drei gleichen jährlichen Tranchen ab einem Jahr nach der Gewährung fällig. In Tabelle I wurden keine Käufe oder Verkäufe von Stammaktien gemeldet.

Nach der Gewährung hält Kersten direkt 175.157 derivative Wertpapiere (Optionen). Die Transaktion stellt eine routinemäßige Aktienvergütung dar und führt aufgrund der ausstehenden Aktienbasis von Cel-Sci nur zu einer unerheblichen Verwässerung. Die Einreichung enthält keine Finanzergebnisse, Prognoseänderungen oder andere Unternehmensereignisse.

false000001958400000195842025-07-292025-07-29

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.  20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported):

July 29, 2025

CHEMED CORPORATION

(Exact name of registrant as specified in its charter)

Delaware

     1-8351

  31-0791746

(State or other
jurisdiction of
incorporation)

(Commission File Number)

(I.R.S. Employer
Identification
Number)

2600 First Financial Center, 255 East 5th Street, Cincinnati, OH 45202

(Address of principal executive offices)             (Zip Code)

Registrant's telephone number, including area code:

(513) 762-6690

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

[_]      Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[_]      Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240-14a-12)

[_]      Pre-commencement communications pursuant to Rule 14d-2(b) under Exchange Act (17 CFR 240-14d-2(b))

[_]      Pre-commencement communications pursuant to Rule 13e-4 (c) under Exchange Act (17 CFR 240-13e-4(c))

Securities registered pursuant to 12(b) of the Act:

 

Title of each class

 

Trading symbol

Name of each exchange on which

registered

Capital stock $1 par value

CHE

NYSE

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.  [_]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  [_]

Page 1 of 3


Item 2.02 Results of Operations and Financial Condition

On July 29, 2025, Chemed Corporation issued a press release announcing its financial results for the quarter ended June 30, 2025. A copy of the release is furnished herewith as Exhibit 99.

Item 5.02 Departure of Directors or Certain Officers; Election of Directors: Appointment of Certain Officers, Compensatory Arrangements of Certain Officers.

(b) Nicholas M. Westfall, Executive Vice President of Chemed Corporation (the “Company”) and Chairman and Chief Executive Officer of Vitas, advised that he is resigning as Chairman and Chief Executive Officer of Vitas effective as of July 29, 2025, to pursue other interests. He will continue as Executive Vice President of Chemed and will assist with the transition of his duties until December 1, 2025. A copy of the press release announcing the events described above is attached hereto as Exhibit 99.

Item 9.01 Financial Statements and Exhibits

d)

Exhibit

 

 

 

 

 

(99) Registrant’s press release dated June 30, 2025

 

 

104 The cover page from this Current Report on Form 8-K formatted in Inline XBRL

Page 2 of 3


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CHEMED CORPORATION

Dated:   July 29, 2025

By:

/s/ Michael D. Witzeman

Michael D. Witzeman

Executive Vice President and Chief Financial Officer

Page 3 of 3

FAQ

How many options did CVM's CEO receive in the latest Form 4?

Geert Kersten was granted 25,000 stock options on 07/28/2025.

What is the exercise price of the newly issued CVM options?

The options have an $8.20 exercise (conversion) price.

When do the options granted to CVM's CEO vest?

They vest in three equal annual installments starting one year after the 07/28/2025 grant date.

What is the expiration date for the CEO’s new CVM options?

The options expire on 07/27/2035.

How many derivative securities does the CEO hold after this transaction?

Following the grant, Kersten beneficially owns 175,157 options.
Chemed Corp

NYSE:CHE

CHE Rankings

CHE Latest News

CHE Latest SEC Filings

CHE Stock Data

6.82B
14.33M
2.17%
97.14%
2.03%
Medical Care Facilities
Services-home Health Care Services
United States
CINCINNATI